D-Artepp is a prescription antimalarial medication manufactured by Guilin Pharmaceutical. It is an Artemisinin-based Combination Therapy (ACT) containing two active ingredients: Dihydroartemisinin and Piperaquine Phosphate. It is widely used for treating acute, uncomplicated malaria infections, particularly those caused by Plasmodium falciparum.
Active Ingredients & Dual Mechanism of Action
-
Dihydroartemisinin (DHA): A potent, fast-acting derivative of artemisinin that rapidly clears malaria parasites from the blood during the initial phase of infection. It generates reactive free radicals that damage cellular structures inside the parasite.
-
Piperaquine Phosphate: A long-acting bisquinoline antimalarial structured similarly to chloroquine. It inhibits the parasite’s ability to process toxic heme in red blood cells, causing cell lysis and eliminating residual parasites over several days to weeks.
Synergistic Advantage: Dihydroartemisinin provides fast symptom relief and parasite reduction within hours, while piperaquine remains in the circulation to clear remaining parasites and prevent reinfection or relapse over a prolonged period.
Dosage Forms & Available Strengths
D-Artepp is manufactured in multiple weight-based strength options:
-
Adult Film-Coated Tablets: 80 mg Dihydroartemisinin / 640 mg Piperaquine Phosphate
-
Pediatric Dispersible Tablets:
-
20 mg Dihydroartemisinin / 160 mg Piperaquine Phosphate
-
40 mg Dihydroartemisinin / 320 mg Piperaquine Phosphate
-
Clinical Indications
-
Uncomplicated Malaria: Indicated for the treatment of acute, uncomplicated malaria caused by Plasmodium falciparum and other Plasmodium species.
-
Note: D-Artepp is not used for malaria prophylaxis (prevention) and is not intended for severe or cerebral malaria requiring intravenous therapy.
Key Pharmacokinetics
-
Absorption: Both components are absorbed orally. Taking piperaquine with water on an empty stomach is standard, though absorption characteristics vary slightly depending on dietary fat intake.
-
Half-Life: Dihydroartemisinin has a short elimination half-life ($\sim 1\text{ hour}$), facilitating immediate action. Piperaquine has a prolonged terminal elimination half-life ($\sim 20\text{ to }30\text{ days}$), providing extended protection against reinfection.
Administration Guidelines
-
3-Day Once-Daily Regimen: D-Artepp is taken once daily for 3 consecutive days (a total of 3 doses).
-
Timing: Doses should ideally be taken at 24-hour intervals.
-
Fasting Requirement: Avoid taking doses alongside high-fat meals, as excessive fat can unpredictably increase piperaquine absorption and risk cardiac side effects.
-
Vomiting: If vomiting occurs within 30 minutes of swallowing a dose, repeat the dose fully. If vomiting happens between 30 and 60 minutes after ingestion, take half the original dose.
Safety Profile & Considerations
-
Common Side Effects: Headache, dizziness, loss of appetite, nausea, vomiting, abdominal pain, fatigue, and coughing.
-
Cardiac Precaution (QT Prolongation): Piperaquine can cause prolongation of the QT interval on an ECG. Caution is required in patients with underlying cardiac arrhythmias, congenital long QT syndrome, uncorrected hypokalemia or hypomagnesemia, or those taking other QT-prolonging drugs.
-
Pregnancy & Lactation: Avoid during the first trimester of pregnancy unless specifically recommended by a physician under high-risk clinical evaluation. It may be used during the second and third trimesters under medical supervision.
-
Key Drug Interactions: Caution when combined with CYP3A4 inhibitors/inducers, antiretrovirals, or antiarrhythmics that affect cardiac conduction.
Note: D-Artepp is a prescription antimalarial. The full 3-day treatment course must be completed to prevent parasite resistance and treatment failure, even if fever and symptoms subside quickly.
Reviews
There are no reviews yet.